• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三磷酸腺苷-氯化镁输注对失血性休克后肝细胞通透性及代谢的影响。

The effect of ATP-MgCl2 infusion on hepatic cell permeability and metabolism after hemorrhagic shock.

作者信息

Machiedo G W, Ghuman S, Rush B F, Kraven T, Dikdan G

出版信息

Surgery. 1981 Aug;90(2):328-35.

PMID:7256545
Abstract

The ability of exogenous ATP-MgCl2 to reverse the inhibition of ATP-dependent intracellular reactions by hemorrhagic shock was studied. Levels of ornithine in the postperfusion fluid were lower in animals receiving ATP-MgCl2 than in placebo-treated control animals (338.6 +/- 167.0 versus 692.1 +/- 67.2 mumol). Arginine levels were higher (399.1 +/- 130.1 versus 34.3 +/- 59.1 mumol) in ATP-MgCl2-treated animals. Ability of in vitro ATP to enter the cell and inhibit lactate formation (Crabtree effect) was significantly less in those animals receiving in vivo ATP-MgCl2 (81.4 +/- 11.1% versus 57.7 +/- 10.1%). Glutamate levels were not decreased by shock but were significantly increased by treatment with ATP-MgCl2 compared to placebo (190.5 +/- 48.8 versus 122.6 +/- 36.3 mumol). These data indicate that exogenously administered ATP-MgCl2 can reverse the inhibition of ornithine metabolism and the changes in lactate inhibition seen in hemorrhagic shock. These are both intracellular ATP-dependent reactions.

摘要

研究了外源性ATP-MgCl₂逆转失血性休克对ATP依赖性细胞内反应抑制作用的能力。接受ATP-MgCl₂的动物灌注后液体中的鸟氨酸水平低于接受安慰剂治疗的对照动物(338.6±167.0对692.1±67.2μmol)。接受ATP-MgCl₂治疗的动物精氨酸水平较高(399.1±130.1对34.3±59.1μmol)。接受体内ATP-MgCl₂的动物中,体外ATP进入细胞并抑制乳酸生成(Crabtree效应)的能力显著降低(81.4±11.1%对57.7±10.1%)。休克并未降低谷氨酸水平,但与安慰剂相比,ATP-MgCl₂治疗显著增加了谷氨酸水平(190.5±48.8对122.6±36.3μmol)。这些数据表明,外源性给予ATP-MgCl₂可逆转失血性休克中鸟氨酸代谢的抑制和乳酸抑制的变化。这两者都是细胞内ATP依赖性反应。

相似文献

1
The effect of ATP-MgCl2 infusion on hepatic cell permeability and metabolism after hemorrhagic shock.三磷酸腺苷-氯化镁输注对失血性休克后肝细胞通透性及代谢的影响。
Surgery. 1981 Aug;90(2):328-35.
2
Effect of intravenous ATP-MgCl2 on cellular function in liver and muscular in hemorrhagic shock.静脉注射三磷酸腺苷-氯化镁对失血性休克时肝脏和肌肉细胞功能的影响。
Curr Surg. 1981 Sep-Oct;38(5):300-4.
3
ATP-MgCl2 treatment prior to hypoxic-hypotension.
Circ Shock. 1983;11(1):65-71.
4
Improved survival and reticuloendothelial function with intravenous ATP-MgCl2 following hemorrhagic shock.出血性休克后静脉注射三磷酸腺苷-氯化镁可改善生存率和网状内皮系统功能。
Circ Shock. 1983;11(2):141-8.
5
Effect of ATP-MgCl2-glucose administration during hemorrhagic shock on cardiovascular function, metabolism, and survival.失血性休克期间给予ATP-氯化镁-葡萄糖对心血管功能、代谢及存活率的影响。
Adv Shock Res. 1980;3:153-66.
6
The use of insulin and glucose during resuscitation from hemorrhagic shock increases hepatic ATP.在失血性休克复苏过程中使用胰岛素和葡萄糖可增加肝脏的三磷酸腺苷(ATP)水平。
J Surg Res. 2000 Aug;92(2):171-6. doi: 10.1006/jsre.2000.5857.
7
No beneficial effect of ATP-MgCl2 on impaired transmembrane potential and protein synthesis in liver ischemia.三磷酸腺苷-氯化镁(ATP-MgCl2)对肝脏缺血时跨膜电位受损和蛋白质合成无有益作用。
Acta Chir Scand. 1982;148(7):601-7.
8
ATP-MgCl2 and liver blood flow following shock and ischemia.休克和缺血后的三磷酸腺苷-氯化镁与肝血流量
Prog Clin Biol Res. 1989;299:19-31.
9
Hemorrhagic shock and hepatic cell membrane permeability.失血性休克与肝细胞膜通透性
Surgery. 1981 Sep;90(3):489-92.
10
[Effect of a protein-free hemoderivative on recovering capability of rat liver following 60 minutes of hemorrhagic shock].[无蛋白血液衍生物对大鼠失血性休克60分钟后肝脏恢复能力的影响]
Arzneimittelforschung. 1975 Mar;25(3):388-92.

引用本文的文献

1
Hypothermia in bleeding trauma: a friend or a foe?出血性创伤患者的低体温:朋友还是敌人?
Scand J Trauma Resusc Emerg Med. 2009 Dec 23;17:65. doi: 10.1186/1757-7241-17-65.
2
Influence of pH on the modification of thiols by carbamoylating agents and effects on glutathione levels in normal and neoplastic cells.pH对氨基甲酰化剂修饰硫醇的影响及其对正常细胞和肿瘤细胞中谷胱甘肽水平的作用。
Cancer Chemother Pharmacol. 1989;24(2):95-101. doi: 10.1007/BF00263127.